ArticleFrontiers in genetics2022
Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- SF1 regulates the transcription of FDX1 to promote cuproptosis in pediatric sepsis-related acute lung injury by interacting with cJUN.Biology direct · 2026Article
- lncRNA RP11-199F11.2 promotes high-grade serous ovarian cancer cell proliferation by regulating cuproptosis through FDX1.Scientific reports · 2025Article
- Identification and validation of cuproptosis-related immune checkpoint expression for glioblastoma.BMC cancer · 2025Article
- Nanoparticles induced cuproptosis to enhance antitumor immunotherapy.Journal of nanobiotechnology · 2025Review
- Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications.Journal of translational medicine · 2025Review
- Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope.Molecular cancer · 2024Review
- Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?Cell communication and signaling : CCS · 2024Review
- PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Cuproptosis: unveiling a new frontier in cancer biology and therapeutics.Cell communication and signaling : CCS · 2024Review
- Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.Heliyon · 2024Review
- IAPP blocks anti-breast cancer function of CD8Frontiers in immunology · 2024Article
- The Role of Cuproptosis Key Factor FDX1 in Gastric Cancer.Current pharmaceutical biotechnology · 2024Article
- The signature genes of cuproptosis associates with tumor immune microenvironment and predicts prognosis in kidney renal clear cell carcinoma.Frontiers in oncology · 2024Article
- Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma.Scientific reports · 2023Article
- Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma.BMC cancer · 2023Article
- Article
- Role of cuproptosis in understanding diseases.Human cell · 2023Review
- The biological significance of cuproptosis-key gene MTF1 in pan-cancer and its inhibitory effects on ROS-mediated cell death of liver hepatocellular carcinoma.Discover oncology · 2023Article
- A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.International journal of molecular sciences · 2023Article
- A Deep Learning Approach for Prognostic Evaluation of Lung Adenocarcinoma Based on Cuproptosis-Related Genes.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.